Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03463694
Other study ID # ELVIS Kids
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2, 2018
Est. completion date September 30, 2023

Study information

Verified date May 2024
Source University of Edinburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ELVIS Kids is a parallel, open label, randomised controlled trial (RCT) of Hypertonic Saline (HS) nose drops (~2.6% NaCl) vs. standard care in children <7 years of age with symptoms of an Upper Respiratory Tract Infection (URTI).


Description:

The study will run over ~30 months. Children are recruited prior to, or within 48 hours of developing URTI symptoms by advertising in areas such as local schools, nurseries, health centres and workplaces as well as social media. For the purposes of this study an URTI is defined as: at least two respiratory symptoms (nasal stuffiness, runny nose, cough, sore throat, or sneezing) OR one respiratory symptoms and at least one systemic symptom (lethargy, muscle pain, headache, pyrexia ≥38°C). Willing parents/guardians, of children <7 years of age, will be directed by the study advertising to contact the research team at their local research site if they are interested in participating. Children will be randomised to either a Control arm of standard symptomatic care, or an Intervention arm of 3 drops each nostril of HS at least 4 times a day until 24 hours after asymptomatic or maximum of 28 days. All participants will be requested to obtain a mid-turbinate nasal swab prior to first nasal HS drops (repeated daily for 5 days), a daily symptom diary (CARIFS, a valid illness measure in the UK), and an end of illness questionnaire (healthcare use, adverse events, acceptability, infection in household contacts, parental time taken off usual activities). Parent/guardian of the children allocated to the intervention arm will be taught how to prepare the HS. Parent/guardian of children who are asymptomatic at recruitment are requested to inform CCRF when the child develops an URTI (within 48 hours) and follow the instructions already provided to them when given the go-ahead to start the trial. On day 28, parents/guardians will be contacted to determine if their child suffered from wheeze either during the illness or at any point until day 28. Participation in the study will end on day 28.


Recruitment information / eligibility

Status Completed
Enrollment 407
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Weeks to 7 Years
Eligibility INCLUSION CRITERIA 1. Children between corrected gestational age of =40 weeks and <7 years of age 2. Children without URTI OR =48 hours of URTI* starting. - A URTI being defined as at least two respiratory symptoms (nasal congestion (i.e. stuffy nose), runny nose, cough, sore throat) OR one respiratory symptom + at least one systemic symptom (Low energy/tired, muscle aches/pains, headache, fever =38°C). EXCLUSION CRITERIA 1. Children needing immediate medical attention 2. Children using saline drops/sprays at the time of randomisation 3. Children on immunosuppressive medication, regular oral/inhaled steroids, regular antibiotics (use of antibiotics is allowed as long as the child does not need regular antibiotics) 4. Children with a known chronic illness (e.g. cystic fibrosis, cardiac, renal, liver, lung, neurological conditions) apart from wheeze or asthma which are not exclusions if the child is otherwise well and not on regular steroids) 5. Children being followed up for developmental delay 6. Children receiving the nasal flu vaccine =14 days ago 7. Children taking part in another interventional trial 8. If parents/guardians indicating that they are unable to comply with the study protocol prior to randomisation 9. If parents/guardians are unable to understand written or spoken English 10. Children randomised to ELVIS KIDS on a previous episode of URTI 11. Children with a concurrently participating sibling

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Na Cl solution
~2.6% NaCl solution prepared from sea salt

Locations

Country Name City State
United Kingdom Childrens' Clinical Research Facility Edinburgh

Sponsors (1)

Lead Sponsor Collaborator
University of Edinburgh

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to the first report that the child is "not unwell". Time until child not unwell Maximum of 28days
Secondary Severity of all symptoms Recorded by parents from options: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable 1-28 days (or until child is well)
Secondary The length of time for individual symptoms to resolve Recorded as: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable 1-28 days (or until child is well)
Secondary Severity of individual symptoms Recorded by parents from options: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable 1-28 days (or until child is well)
Secondary Contacting healthcare (NHS 24, OOH, GP) -Number of participants Number of participants 1-28 days (or until child is well)
Secondary Contacting healthcare (NHS 24, OOH, GP) -Frequency of contacts Number of contacts 1-28 days (or until child is well)
Secondary Participants needing GP appointments- Number of participants Number of appointments 1-28 days (or until child is well)
Secondary Participants needing GP appointments- Frequency of contacts Number of appointments 1-28 days (or until child is well)
Secondary Number of participants attending hospital and diagnosis - Number of participants Number of participants 1-28 days (or until child is well)
Secondary Number of participants attending hospital and diagnosis - Frequency of contacts Number of attendances 1-28 days (or until child is well)
Secondary Length of stay in hospital if admitted Length in Days 1-28 days (or until child is well)
Secondary Number of participants reporting wheeze during illness and between end of illness to 28 days Number reporting wheeze Day 28
Secondary Number of participants reporting over the counter medication use Number of participants 1-28 days (or until child is well)
Secondary Duration of viral shedding Viral shedding duration in days Days 1-5
Secondary Reduction in viral shedding Log conversion of each positive result will be done using the following formula: (40-CT of specimen)/3.3 to estimate change in shedding. Days 1-5
Secondary Rate of reduction in viral shedding Rate of viral shedding duration in days Days 1-5
Secondary Reduction in transmission to household contacts Questionnaire - reported number of adults and children catching URTI 1-28 days (or until child is well)
Secondary Number of participants reporting side effects of nasal drops Side effects reported 1-28 days (or until child is well)
Secondary Types and severity of side effects reported Side effects reported 1-28 days (or until child is well)
Secondary Number of days lost from school/nursery for child Number of days 1-28 days (or until child is well)
Secondary Number of days lost from work for parent/guardian Number of days 1-28 days (or until child is well)
Secondary Cost of over the counter medication used Cost of medicine used. 1-28 days (or until child is well)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05818644 - Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Not yet recruiting NCT04523623 - Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries N/A
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT03385681 - Pediatric Pain Management - an Intervention Study N/A
Completed NCT00229671 - Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics N/A
Completed NCT04465370 - Pediatric Cardiac Output Monitoring Observational Study
Recruiting NCT04100070 - Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study N/A
Not yet recruiting NCT06035757 - The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery Phase 4
Completed NCT03369847 - Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge Phase 4
Completed NCT05474170 - Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest N/A
Recruiting NCT05230004 - Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth N/A
Completed NCT05818215 - Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns
Completed NCT05731401 - Expressed Beliefs About the Cause of Pain in a Paediatric Population
Completed NCT06376188 - Improving Breaking Bad News in Pediatrics by Simulated Communication N/A
Completed NCT04589910 - Measuring Thickness of the Normal Diaphragm in Children Via Ultrasound. N/A
Recruiting NCT04252508 - Impact of a Double-reading Animated Film (Child, Parents) in Preoperative on the Anxiety of Children Upon Arrival at the Operating Room N/A
Completed NCT04655378 - Validation of the IgA1 Detection Method With Gradient Glycosylation by Mass Spectrometry as a Potential Marker of Renal Involvement in Pediatric Rheumatoid Purpura
Completed NCT04610918 - Comparing Body Composition Assessment Methods
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1